More than 1.9 million Canadians have Chronic Kidney Disease.
We hope to reduce the burden of disease by early identification and prevention through education.
More than 1.9 million Canadians have Chronic Kidney Disease.
We hope to reduce the burden of disease by early identification and prevention through education.
SGLT2 inhibition has been shown to provide cardioprotective and renal protective effects. In this talk, Dr. Robert Ting presents recent clinical data on SGLT2i and reviews their place in the management of Canadians patients with chronic kidney disease (CKD), with or without type 2 diabetes (T2D).
Albuminuria is associated with a higher risk of progressive renal disease leading to dialysis, and more importantly, a greater risk of cardiovascular (CV) outcomes. This presentation by Dr. Sheldon Tobe examines the impact of proteinuria and its treatment on clinical outcomes. Novel approaches discussed included the use of sodium-glucose cotransporter-2 inhibitors (SGLT2i) and non-steroidal mineralocorticoid receptor antagonist (MRA), finerenone.
Accurate estimation of glomerular filtration rate (GFR) is essential for the diagnosis, staging, and management of chronic kidney disease (CKD). This presentation by Dr. Tabo Sikaneta offers an overview of the evolution of GFR estimation.
